Organovo Announces Close of the Sale of FXR Program to Eli Lilly and Company

Core Insights - Organovo Holdings, Inc. has successfully closed the sale of its FXR program, including the lead asset FXR314, to Eli Lilly and Company on March 25, 2025 [1][2] Company Overview - Organovo is a clinical stage biotechnology company focused on developing drugs that are effective in three-dimensional (3D) human tissues, utilizing proprietary technology to create 3D human tissues that replicate key aspects of native human tissue [3]